Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
Q3 2023 vs. Q2 2023
How the institutions holding Ambrx Biopharma, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 42 | 1 | 44 | +3 |
| Shares | 47.9M | 100 | 49.4M | +1.50M (+3.1%) |
| Value | $788.8M | $1.65K | $568.3M | −$220.5M (−28.0%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Ambrx Biopharma, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Federated Hermes, Inc. | 2,395,867 | $27.6M | 0.07% |
| Ally Bridge Group (NY) LLC | 281,089 | $3.23M | 3.79% |
| Macquarie Group Ltd | 250,000 | $2.88M | 0.00% |
| Nwi Management LP | 160,935 | $1.85M | 0.32% |
| Parkman Healthcare Partners LLC | 150,000 | $1.73M | 0.32% |
| Logos Global Management LP | 115,000 | $1.32M | 0.19% |
| Monashee Investment Management LLC | 70,000 | $805.0K | 0.34% |
| State Street Corp | 50,400 | $579.6K | 0.00% |
| Bank of New York Mellon Corp | 47,433 | $545.5K | 0.00% |
| Alliancebernstein L.P. | 47,296 | $543.9K | 0.00% |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 31,735 | $365.0K | 0.01% |
| Royal Bank of Canada | 6,500 | $75.0K | 0.00% |
| UBS Group AG | 5,574 | $64.1K | 0.00% |
| Group One Trading, L.P. | 2,155 | $24.8K | 0.00% |
| Legal & General Group Plc | 1,381 | $15.9K | 0.00% |
| Tower Research Capital LLC (TRC) | 235 | $2.70K | 0.00% |
Sold out (13)
Institutions that held Ambrx Biopharma, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Farallon Capital Management, L.L.C. | 2,269,000 | $37.3M |
| Artal Group S.A. | 702,291 | $11.6M |
| Point72 Asset Management, L.P. | 349,938 | $5.76M |
| JPMorgan Chase & Co | 157,858 | $2.60M |
| Moore Capital Management, LP | 144,400 | $2.38M |
| Silverarc Capital Management, LLC | 100,000 | $1.65M |
| Schonfeld Strategic Advisors LLC | 98,600 | $1.62M |
| Susquehanna International Group, LLP | 51,290 | $844.2K |
| Jane Street Group, LLC | 17,538 | $288.7K |
| Belvedere Trading LLC | 13,872 | $228.3K |
| QP Wealth Management, LLC | 12,670 | $208.5K |
| Exchange Traded Concepts, LLC | 9,830 | $161.7K |
| Aquatic Capital Management LLC | 400 | $7.00K |
Not filed for Q3 2023 yet (1)
Institutions that held Ambrx Biopharma, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| BerganKDV Wealth Management, LLC | 100 | $1.65K |